NCT06295471 A Comparative Clinical Study to Assess Pain Score and Wound Healing Following Fractional Ablation With a DFG Laser and CO2 Laser
| NCT ID | NCT06295471 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 23 participants |
| Start Date | 2024-10-16 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 23 participants in total. It began in 2024-10-16 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study aims assess whether the Difference Frequency Generation (DFG) laser could be a better alternative to the CO2 laser in terms of reduced side effects and patient downtime.
Eligibility Criteria
Inclusion Criteria: * Subjects must be able and willing to provide written informed consent and comply with the requirements of the study protocol; * Subjects must be in good general health, based on answers provided during the screening visit; * Subjects must be able to read and understand English. * Subjects must be above the age of 18. * Subjects must have no history of skin conditions that affect the integrity of the skin barrier. Exclusion Criteria: * Are pregnant or lactating; * Have a history of drug or alcohol abuse or have reported habitual alcohol intake greater than 2 standard drinks per day \[e.g., 2 beers, 2 glasses of wine, or 2 mixed drinks\]; * Are smoking or have a history of smoking; * Presence of eczema, psoriasis, skin wounds or ulcers, or any other skin disease on the thighs; * Have birth marks, tattoos, scars, or any other disfiguration of the skin in the skin area of interest; * Presence of sunburn or tan in the treatment area; * Use of any topical application of retinoids in the area of interest or systemic retinoids in the past 6 months; * Use of any prescription topical medication, such as corticosteroids or hydroquinone on the skin area of interest in the past 6 months; * History of blood-clotting abnormality; * History of keloid formation or hypertrophic scarring; * History of allergic reaction to local anesthesia, aluminum chloride, and/or glycerol; * Investigator, interfere with study evaluations or pose a risk to subject safety during the study; * Exhibits any clinical conditions or takes any medication which in the opinion of the investigator may interfere with the study or pose a risk to subject safety during the study; * Is not able to follow study protocol.
Contact & Investigator
Dieter Manstein, MD, PhD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06295471 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06295471 currently recruiting?
Yes, NCT06295471 is actively recruiting participants. Contact the research team at mansteinlab@mgh.harvard.edu for enrollment information.
Where is the NCT06295471 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06295471 clinical trial?
NCT06295471 is sponsored by Massachusetts General Hospital. The principal investigator is Dieter Manstein, MD, PhD at Massachusetts General Hospital. The trial plans to enroll 23 participants.